Ribo and Madrigal hit first clinical milestone on siRNA therapy programme for MASH
July 02, 2026 | 16:37
Suzhou Ribo Life Science (06938.HK) and Madrigal Pharmaceuticals (Nasdaq: MDGL) reached the first major milestone in their collaboration developing siRNA therapies targeting metabolic dysfunction-associated steatohepatitis.
Latest News
Mobile Version